These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 18406001

  • 1. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
    Akinci B, Demir T, Saygili S, Yener S, Alacacioglu I, Saygili F, Bayraktar F, Yesil S.
    Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
    [Abstract] [Full Text] [Related]

  • 2. Levels of thrombin activatable fibrinolysis inhibitor in gestational diabetes mellitus.
    Gumus II, Kargili A, Karakurt F, Kasapoglu B, Derbent A, Kaygusuz I, Koca C, Sevgili S.
    Gynecol Endocrinol; 2013 Apr; 29(4):327-30. PubMed ID: 23327722
    [Abstract] [Full Text] [Related]

  • 3. Plasma thrombin-activatable fibrinolysis inhibitor levels are not associated with glucose intolerance and subclinical atherosclerosis in women with previous gestational diabetes.
    Akinci B, Celtik A, Yener S, Genc S, Tunali S, Yuksel F, Ozcan MA, Secil M, Yesil S.
    Clin Appl Thromb Hemost; 2011 Apr; 17(6):E224-30. PubMed ID: 21406417
    [Abstract] [Full Text] [Related]

  • 4. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 6. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy.
    Watanabe T, Minakami H, Sakata Y, Matsubara S, Sato I, Suzuki M.
    Gynecol Obstet Invest; 2004 Oct; 58(1):19-21. PubMed ID: 15004439
    [Abstract] [Full Text] [Related]

  • 7. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006 Oct; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 8. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [Abstract] [Full Text] [Related]

  • 9. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 10. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R.
    Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
    [Abstract] [Full Text] [Related]

  • 11. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
    Farhan S, Winzer C, Tura A, Quehenberger P, Bieglmaier C, Wagner OF, Huber K, Waldhäusl W, Pacini G, Kautzky-Willer A.
    Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
    [Abstract] [Full Text] [Related]

  • 12. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.
    Alacacioğlu I, Ozcan MA, Alacacioğlu A, Polat M, Yüksel F, Demirkan F, Pişkin O, Ozgenç Y, Ozsan HG, Undar B.
    Thromb Res; 2004 May; 114(3):155-9. PubMed ID: 15342211
    [Abstract] [Full Text] [Related]

  • 13. Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: relative contribution of TAFI and PAI-1.
    Semeraro F, Giordano P, Faienza MF, Cavallo L, Semeraro N, Colucci M.
    Thromb Haemost; 2012 Aug; 108(2):311-7. PubMed ID: 22740053
    [Abstract] [Full Text] [Related]

  • 14. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 Aug; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 15. Coagulation and fibrinolysis parameters in normal pregnancy and in gestational diabetes.
    Bellart J, Gilabert R, Fontcuberta J, Carreras E, Miralles RM, Cabero L.
    Am J Perinatol; 1998 Aug; 15(8):479-86. PubMed ID: 9788646
    [Abstract] [Full Text] [Related]

  • 16. Fibrinolytic dysfunction after gestation is associated to components of insulin resistance and early type 2 diabetes in latino women with previous gestational diabetes.
    Morimitsu LK, Fusaro AS, Sanchez VH, Hagemann CC, Bertini AM, Dib SA.
    Diabetes Res Clin Pract; 2007 Dec; 78(3):340-8. PubMed ID: 17544539
    [Abstract] [Full Text] [Related]

  • 17. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [Abstract] [Full Text] [Related]

  • 18. The role of fibrinolytic and antifibrinolytic activities in the pathophysiology of HELLP syndrome.
    Guven S, Sonmez M, Karahan SC.
    Hypertens Pregnancy; 2011 Jul; 30(3):275-86. PubMed ID: 19943771
    [Abstract] [Full Text] [Related]

  • 19. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
    Ozeren M, Karahan SC, Ozgur M, Eminagaoglu S, Unsal M, Baytan S, Bozkaya H.
    Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
    [Abstract] [Full Text] [Related]

  • 20. Thrombin activatable fibrinolysis inhibitor (TAFI) in human amniotic fluid. A preliminary study.
    Uszyński W, Uszyński M, Zekanowska E.
    Thromb Res; 2007 Oct; 119(2):241-5. PubMed ID: 16540154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.